Ralf Gold

Active 1970–2026

293
Papers
36,913
Citations
103
h-index
275
i10-index

Citations

Citations per year for Ralf Gold1971: 1 citations1972: 1 citations1973: 2 citations1976: 2 citations1977: 2 citations1978: 1 citations1979: 1 citations1981: 1 citations1985: 2 citations1986: 2 citations1993: 1 citations1994: 13 citations1995: 53 citations1996: 51 citations1997: 76 citations1998: 79 citations1999: 76 citations2000: 64 citations2001: 76 citations2002: 74 citations2003: 75 citations2004: 58 citations2005: 68 citations2006: 101 citations2007: 109 citations2008: 117 citations2009: 156 citations2010: 231 citations2011: 228 citations2012: 218 citations2013: 332 citations2014: 272 citations2015: 379 citations2016: 295 citations2017: 280 citations2018: 342 citations2019: 1,139 citations2020: 1,439 citations2021: 1,497 citations2022: 1,325 citations2023: 969 citations2024: 1,570 citations2025: 876 citations2026: 32 citations1974–1975: no citations, so these years are not shown1980: no citations, so this year is not shown1982–1984: no citations, so these years are not shown1987–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,359 citing papers, 20.4% of this breakdownGermany: 1,911 citing papers, 11.6% of this breakdownChina: 1,390 citing papers, 8.4% of this breakdownUnited Kingdom: 1,061 citing papers, 6.4% of this breakdownItaly: 966 citing papers, 5.9% of this breakdownCanada: 635 citing papers, 3.9% of this breakdownFrance: 546 citing papers, 3.3% of this breakdownSwitzerland: 531 citing papers, 3.2% of this breakdownSpain: 524 citing papers, 3.2% of this breakdownAustralia: 457 citing papers, 2.8% of this breakdownNetherlands: 457 citing papers, 2.8% of this breakdownJapan: 384 citing papers, 2.3% of this breakdown
0%20.4%Other 25.8%

Fields

  • Medicine51.7%
  • Biochemistry, Genetics and Molecular Biology20.5%
  • Neuroscience16.1%
  • Immunology and Microbiology8.4%
  • Nursing0.7%
  • Agricultural and Biological Sciences0.6%
  • Other2%

Topics

  • Multiple Sclerosis Research Studies9.4%
  • Neuroinflammation and Neurodegeneration Mechanisms6.2%
  • Peripheral Neuropathies and Disorders4.1%
  • Gut microbiota and health2.5%
  • Neurogenesis and neuroplasticity mechanisms1.9%
  • Immune cells in cancer1.9%
  • Other74%

Coauthors

All papers

Open in search
  1. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution

    Authors: , , , , , , , , , , , , , , , , , , - Nature 2019 cited by 1,375

  2. Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carsten Lukas, Sören Gatermann, Markus Scholz, H. Przuntek, Marco Prinz, Sofia K. Forslund, Konstanze F. Winklhofer, Dominik N. Müller, Ralf A. Linker, Ralf Gold, Aiden Haghikia - Cell 2020 cited by 647

  3. Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine

    Authors: , , , , , , , , , , , , , , , , , , , , , - Immunity 2015 cited by 920

  4. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aiden Haghikia, Ulf Landmesser - European Heart Journal 2021 cited by 355

  5. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mihaela Bejinariu, Florian Then Bergh, Arnfin Bergmann, Evanthia Bernitsas, Achim Berthele, Virender Bhan, Felix Bischof, Randall J. Bjork, Gregg Blevins, Matthias Boehringer, Thomas Boerner, Robert Bonek, James D. Bowen, Allen C. Bowling, Alexey Boyко, Cavit Boz, Vera Bracknies, Stefan Braune, Vincenzo Brescia Morra, Bruno Brochet, Waldemar Brola, Paul Brownstone, M Brozman, Donald Brunet, Ioan Buraga, Margaret Burnett, Mathias Buttmann, Helmut Butzkueven, Jonathan Cahill, Jonathan Calkwood, William Camu, Mark Cascione, G. Castelnovo, Diego Centonze, João Cerqueira, Andrew Chan, Andrea Cimprichová, Stanley Cohan, Giancarlo Comi, Jill Ker Conway, Joanna A. Cooper, John R. Corboy, Jorge Correale, Brian Costell, David A. Cottrell, Patricia K. Coyle, Matthew Craner, Liying Cui, Luı́s Cunha, Anna Członkowska, Ana Silva, Joao de, de Sèze, Marc Debouverie, Jan Debruyne, D. Decoo, G. Defer, Tobias Derfuß, Norma Deri, Bhupesh Dihenia, Péter Diószeghy, Vladimír Donáth, Bénédicte Dubois, Martin Duddy, Pierre Duquette, Gilles Edan, Hüsnü Efendi, Stanton B. Elias, Peter Emrich, Bonaventura Casanova Estruch and 228 more - The Lancet 2018 cited by 925

  6. Anti-CD19 CAR T cells for refractory myasthenia gravis

    Authors: , , , , , , , , , , - The Lancet Neurology 2023 cited by 149

  7. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

    Authors: , , , - Nature Reviews Drug Discovery 2019 cited by 457

  8. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

    Authors: , , , , , , , , , , - New England Journal of Medicine 2012 cited by 1,703

  9. Advancements and challenges in CAR T cell therapy in autoimmune diseases

    Authors: , , , , , , , , , , , , , - Nature Reviews Rheumatology 2024 cited by 209

  10. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

    Authors: , , , , , , , , , , , , , , , , , - Brain 2011 cited by 1,168

  11. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Multiple Sclerosis Journal 2018 cited by 705

  12. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fritz Leutmezer, Volker Limmroth, Jan D. Lünemann, Andreas Lutterotti, Sven G. Meuth, Uta Meyding‐Lamadé, Michael Platten, Peter Rieckmann, Stephan Schmidt, Hayrettin Tumani, Frank Weber, Martin S. Weber, Uwe K. Zettl, Tjalf Ziemssen, Frauke Zipp, for the ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG) - Therapeutic Advances in Neurological Disorders 2021 cited by 191

  13. Sex and gender issues in multiple sclerosis

    Authors: , , - Therapeutic Advances in Neurological Disorders 2013 cited by 524

  14. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stefanie Behnke, Stefan Bittner, Franziska Buetow, Mathias Buttmann, Ankelien Duchow, Daniel Engels, Thorleif Etgen, Katinka Fischer, Benedikt Frank, Anna Gahlen, Achim Gass, Johannes Gehring, Christian Geis, Ralf Gold, Yasemin Göreci, Jonas Graf, Sergiu Groppa, Matthias Grothe, Julia Gutbrod, Kersten Guthke, Axel Haarmann, Maria Hastermann, Bernhard Hemmer, Mariella Herfurth, Marina Herwerth, Frank Hoffmann, Olaf Hoffmann, Martin W. Hümmert, Leila Husseini, Jutta Junghans, Matthias Kaste, Peter Kern, Karsten Kern, Pawel Kermer, Christoph Kleinschnitz, Wolfgang Köhler, Kimberly Körbel, Markus C. Kowarik, Markus Kraemer, Julian Reza Kretschmer, Natalia Kurka, Theodoros Ladopoulus, Ann-Sophie Lauenstein, Sarah Laurent, De-Hyung Lee, Dominik Lehrieder, Frank Leypoldt, Martin Liebetrau, Ralf A. Linker, Gero Lindenblatt, Lisa Lohmann, Felix Lüssi, Peter Luedemann, Michelle Maiworm, Martin Marziniak, Christoph Mayer, Stefanie Meister, Mathias Mering, Imke Metz, Sven G. Meuth, Jasmin Naumann, Oliver Neuhaus, Tradite Neziraj, Moritz Niederschweiberer, Sabine Niehaus, Carolin Otto, Florence Pache, Thivya Pakeerathan, Sarah Passoke, Marc Pawlitzki and 40 more - Journal of Neurology 2023 cited by 232

  15. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis

    Authors: , , , , , , , , , , , - Annals of the Rheumatic Diseases 2024 cited by 64

  16. Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Caspar Seitz, Silke Tonner, Christian Urbanek, Simone Zittel, Robert Markewitz, Mirjam Korporal‐Kuhnke, Thomas Schmitter, Carsten Finke, Norbert Brüggemann, Corinna Bien, Ingo Kleiter, Ralf Gold, Klaus-Peter Wandinger, Gregor Kuhlenbäumer, Frank Leypoldt, Ilya Ayzenberg, Frank Leypoldt, Nico Melzer, Kristin Stefanie Melzer, Christian Geis, Ilya Ayzenberg, Andreas van Baalen, Annette Baumgärtner, Robert L. Berger, Franz Blaes, Astrid Blaschek, Kathrin Doppler, Friedrich Ebinger, Dominique Endres, Jürgen Faiss, Alexander Finke, Carsten Finke, Andre Dik, Paul Friedemann, Manuel A. Friese, Anna Gorsler, Catharina C. Groß, Robert Handreka, Martin Häusler, Valentin Held, Frank Hoffmann, Ulrich Hofstadt-van Oy, Christoph Kellinghaus, Andrea Kraft, Markus Krämer, Christos Krogias, Peter Körtvélyessy, Tanja Kümpfel, Jan Lewerenz, Andeas Linsa, Til Menge, Wolfgang Heide, Joachim Havla, Michael P. Malter, Sven G. Meuth, Constanze Mönig, Marie‐Luise Mono, Michael Nagel, Jost Obrocki, Felix von Poderwils, Josef Priller, Gernot Reimann, Marius Ringelstein, Kevin Rostásy, G Seidel, Oliver Stammel, Muriel Stoppe, Claudia Sommer, Kurt‐Wolfram Sühs, Max Kaufmann and 100 more - Brain 2022 cited by 117

  17. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells

    Authors: , , , , , , , , , , - Neuron 2024 cited by 69

  18. Association of obesity with disease outcome in multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2022 cited by 86

  19. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elisabeth Gulowsen Celius, Helle Bach Søndergaard, Jesper Tegnér, Hanne F. Harbo, Annette Oturai, Sigurgeir Ólafsson, Hannes P. Eggertsson, Bjarni V. Halldórsson, Haukur Hjaltason, Elías Ólafsson, Ingileif Jónsdóttir, Kāri Stefánsson, Tomas Olsson, Fredrik Piehl, Tomas J. Ekström, Ingrid Kockum, Andrew P. Feinberg, Maja Jagodic - Nature Communications 2018 cited by 212

  20. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frauke Zipp - EBioMedicine 2020 cited by 131

  21. Propionic Acid Rescues High-Fat Diet Enhanced Immunopathology in Autoimmunity via Effects on Th17 Responses

    Authors: , , , , , , , , - Frontiers in Immunology 2021 cited by 57

  22. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Axel Haarmann, Sven Jarius, Brigitte Wildemann, Matthias Grothe, Nadja Siebert, Klemens Ruprecht, Friedemann Paul, Nicolas Collongues, Romain Marignier, Michael Levy, Michael Karenfort, Michael Deppe, Philipp Albrecht, Kerstin Hellwig, Ralf Gold, Hans‐Peter Hartung, Sven G. Meuth, Ingo Kleiter, Orhan Aktaş, on behalf of the Neuromyelitis Optica Study Group (NEMOS) - Neurology Neuroimmunology & Neuroinflammation 2021 cited by 147

  23. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

    Authors: , , , , , , , , , , , - Journal of Neurology 2021 cited by 97

  24. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome

    Authors: , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2024 cited by 71